The sialoglycan-Siglec glyco-immune checkpoint – a target for improving innate and adaptive anti-cancer immunity
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Introduction: During cancer progression, tumor cells develop several mechanisms to prevent killing and to shape the immune system into a tumor-promoting environment. One of such regulatory mechanism is the overexpression of sialic acid (Sia) on carbohydrates of proteins and lipids on tumor cells. Sia-containing glycans or sialoglycans were shown to inhibit immune effector functions of NK cells and T cells by engaging inhibitory Siglec receptors on the surface of these cells. They can also modulate the differentiation of myeloid cells into tumor-promoting M2 macrophages.Areas covered: We review the role of sialoglycans in cancer and introduce the Siglecs, their expression on different immune cells and their interaction with cancer-associated sialoglycans. The targeting of this sialoglycan-Siglec glyco-immune checkpoint is discussed along with potential therapeutic approaches. Pubmed was searched for publications on Siglecs, sialic acid, and cancer.Expert opinion: The targeting of sialoglycan-Siglec interactions has become a major focus in cancer research. New approaches have been developed that directly target sialic acids in tumor lesions. Targeted sialidases that cleave sialic acid specifically in the tumor, have already shown efficacy; efforts targeting the sialoglycan-Siglec pathway for improvement of CAR T cell therapy are ongoing. The sialoglycan-Siglec immune checkpoint is a promising new target for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Getting to the site of inflammation: the leukocyte adhesion cascade updated
Ley, K., Laudanna, C., Cybulsky, M. I., & Nourshargh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2156 · Cited by 4,354 · cited 1×
“Interactions of sialoglycans with selectins mediate leukocyte trafficking [22,23].”
BackgroundVarki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635 · cited 1×
“Glycans are chains of carbohydrates that are attached to proteins or lipids or they can be secreted into the extracellular matrix as long chains of glycosaminoglycans [1,2].”
BackgroundSingle-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors
Villani, A.-C., Satija, R., Reynolds, G., Sarkizova, S., Shekhar, K., Fletcher, J., Griesbeck, M., Butler, A., Zheng, S., Lazo, S., et al. (2017) · Science · doi:10.1126/science.aah4573 · Cited by 2,413 · cited 3×
“Siglec-1 Monocytes (activated) [96] Siglec-7 Neutrophils [59] Macrophages (lymphoid organs, liver, BM, lung, colon, brain) [98] Eosinophils [65] pDCs (subset) [79] Basophils [67] in vitro generated DCs (activated) [85] Mast cells [52,67] Siglec-2 Basophils (special isoform) [69,70] monocytes [59,78] pDCs [77] in vitro…”
BackgroundSiglec-mediated regulation of immune cell function in disease
Macauley, M. S., Crocker, P. R., & Paulson, J. C. (2014) · Nature Reviews Immunology · doi:10.1038/nri3737 · Cited by 1,122
The tumour glyco-code as a novel immune checkpoint for immunotherapy
RodrÍguez, E., Schetters, S. T. T., & van Kooyk, Y. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2018.3 · Cited by 473
Sialic acids in cancer biology and immunity
Pearce, O. M. T., & Läubli, H. (2016) · Glycobiology · doi:10.1093/glycob/cwv097 · Cited by 470
Carlin, A. F., Uchiyama, S., Chang, Y.-C., Lewis, A. L., Nizet, V., & Varki, A. (2009) · Blood · doi:10.1182/blood-2008-11-187302 · Cited by 401
Izquierdo-Useros, N., Lorizate, M., Puertas, M. C., Rodriguez-Plata, M. T., Zangger, N., Erikson, E., Pino, M., Erkizia, I., Glass, B., Clotet, B., et al. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001448 · Cited by 244 · cited 2×
“Siglec-1 Monocytes (activated) [96] Siglec-7 Neutrophils [59] Macrophages (lymphoid organs, liver, BM, lung, colon, brain) [98] Eosinophils [65] pDCs (subset) [79] Basophils [67] in vitro generated DCs (activated) [85] Mast cells [52,67] Siglec-2 Basophils (special isoform) [69,70] monocytes [59,78] pDCs [77] in vitro…”
BackgroundZhang, J. Q., Nicoll, G., Jones, C., & Crocker, P. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002788200 · Cited by 229 · cited 1×
“Siglec-1 Monocytes (activated) [96] Siglec-7 Neutrophils [59] Macrophages (lymphoid organs, liver, BM, lung, colon, brain) [98] Eosinophils [65] pDCs (subset) [79] Basophils [67] in vitro generated DCs (activated) [85] Mast cells [52,67] Siglec-2 Basophils (special isoform) [69,70] monocytes [59,78] pDCs [77] in vitro…”
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Insights into the role of sialylation in cancer progression and metastasis
Dobie, C., & Skropeta, D. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01126-7 · Cited by 348
Foote, C. A., Soares, R. N., Ramirez‐Perez, F. I., Ghiarone, T., Aroor, A., Manrique‐Acevedo, C., Padilla, J., & Martinez‐Lemus, L. (2022) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2022.tb00232.x · Cited by 89
Metadata
- Authors
- Bärenwaldt, A., & Läubli, H.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2019-09-23
- Volume
- 23
- Issue
- 10
- Pages
- 839-853
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2974567434
- Cited by
- 92
- References
- 17
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The sialoglycan-Siglec glyco-immune checkpoint – a target for improving innate and adaptive anti-cancer immunity. https://app.cochat.ai/papers/10.1080/14728222.2019.1667977
- The paper
- Bärenwaldt, A., & Läubli, H. (2019). The sialoglycan-Siglec glyco-immune checkpoint – a target for improving innate and adaptive anti-cancer immunity. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2019.1667977
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.